ISRCTN15458851已完成1 期
A Phase I, double-blind, randomised, single-centre, parallel-group, single ascending dose, placebo-controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of CpG ODN D35 after subcutaneous administration in healthy male subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Male healthy subjects 18 to 50 years old at the time of obtaining the informed consent
- •2. Body weight =60 kg to =90 kg, BMI 18 to 30.1 kg/m². BMI = body weight (kg) / [height (m)]²
- •3. Provision of written informed consent to participate as shown by a signature on the participant information sheet and consent form, after reading the information sheet and consent form, and after having the opportunity to discuss the trial with the Investigator or his/her delegate
- •4. Normal blood pressure: systolic blood pressure between =100 and =140 mmHg, diastolic blood pressure =90 mmHg, measured after 10 min rest in a supine position at Screening, admission, and pre-dose
- •5. A resting heart rate (HR) between =45 and =90 bpm measured after 10 min rest in a supine position at Screening, admission, and pre-dose
- •6. ECG recording without clinically significant abnormality, including a QTcF measure of =450 msec
- •7. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the participant) from first dose until 3 months after the last dose of IMP
- •8. No clinically significant history of previous allergy/sensitivity to CpG ODN D35 or any of the excipients contained within the IMP(s)
- •9. No clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the IMP
- •10. Participant with a negative urinary drugs of abuse (DOA) screen (including alcohol/cotinine) test results, determined within 28 days before the first dose administration of the IMP (N.B.: a positive test result may be repeated at the Investigator’s discretion)
- •11. Participant must be available to complete the study (including all follow-up visits)
- •12. Participant must satisfy an Investigator about his fitness to participate in the study
排除标准
- •1. Behavioural, cognitive, or psychiatric disease that in the opinion of the Investigator affects the ability of the participant to understand and cooperate with the study protocol
- •2. History of clinically significant cardiovascular, renal, hepatic, neurological (especially seizures), immunological, psychiatric, myopathies, bleeding tendency, respiratory and particularly GI disease, especially peptic ulceration and chronic gastritis, GI bleeding, ulcerative colitis, Crohn’s disease or irritable bowel syndrome, as judged by the Investigator
- •3. Individual or family history of pre-existing autoimmune or antibody-mediated diseases including (but not limited to): systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, type 1 diabetes mellitus, auto-immune thyroiditis, Basedow syndrome, autoimmune thrombocytopenia; or proteinuria (greater than trace protein on urine dipstick testing)
- •4. History of allergy, hay fever, intolerance or photosensitivity to any drug or have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug
- •5. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (including non-steroidal anti-inflammatory drugs (NSAID)) in the 28 days or 5 half-lives (whichever is longer) before IMP administration. Administration of up to 3 g of paracetamol per day within 7 days of IMP administration is allowed
- •6. Subjects who have received any prophylactic vaccine (including COVID-19 vaccine) or immunization within the last 28 days or use of corticosteroids or immunosuppressive drugs within 28 days of IMP administration
- •7. Subjects with febrile illness or infectious illness within 2 weeks of IMP administration
- •8. Subjects with positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) and or human immunodeficiency virus (HIV) tests results at Screening
- •9. Positive RT-PCR COVID-19 test at admission
- •10. Donation or loss of greater than 500 ml of blood within the previous 3 months prior to IMP administration
- •11. Major surgery within 12 weeks prior to Screening
- •12. Subjects who are known or suspected alcohol abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 ml of pure alcohol). Positive alcohol test at Screening or admission
- •13. Demonstrating excess caffeine/xanthine consumption (more than 6 cups of coffee or equivalent a day)
- •14. History of use of drugs of abuse in the past 2 years
- •15. Subjects who do not have suitable veins for multiple venepunctures/cannulation
- •16. Subjects who have any clinical condition or prior therapy which, in the opinion of the Investigator, could jeopardize the safety or rights of a volunteer participating in the trial or would render them unable to comply with the protocol
- •17. Participation in a non-marketed drug clinical study within 3 months or five half-lives (whichever is longer) or a marketed drug clinical study within 30 days or five half-lives (whichever is longer) before the first dose of IMP (washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study)
- •18. Subjects who are study site employees, or immediate family members of a study site or sponsor employee
- •19. Inability to communicate well with the Investigators (i.e., language problem, poor mental development or impaired cerebral function)
- •20. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within th
研究者
相似试验
已完成
1 期
A study to investigate the safety, tolerability and activity of multiple ascending doses of DNDI-0690 in healthy volunteers including assessment of heart and kidney functioThe safety, tolerability and fluid exposure of a drug aimed to treat visceral and cutaneous leishmaniasis in healthy volunteersISRCTN30122193Drugs for Neglected Diseases Initiative45
已完成
1 期
A Phase 1, Safety and Pharmacokinetic Study of CSL312 in Healthy SubjectsHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersInflammatory and Immune System - Other inflammatory or immune system disordersHereditary AngioedemaACTRN12616001438448CSL Limited48
已完成
1 期
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of ascending multiple oral doses of XW10172 in healthy adult subjectsarcolepsyNarcolepsyInflammatory and Immune System - Autoimmune diseasesNeurological - Other neurological disordersACTRN12618001038280XW Laboratories (Australia) Pty Ltd24
已完成
1 期
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of ascending single oral doses of XW10172 in healthy adult subjectsACTRN12618000127202XW Laboratories (Australia) Pty Ltd50
已完成
1 期
Study to test the safety and tolerability of a new drug (DNDI-0690) in healthy subjectsVisceral leishmaniasis, cutaneous leishmaniasisInfections and InfestationsISRCTN14683791Drugs for Neglected Diseases Initiative64